Express News | CA Governor Newsom Proclaimed State Of Emergency To Further Enhance State's Preparedness And Accelerate The Bird Flu Cross-Agency Response Efforts
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
European Equities Traded in the US as American Depositary Rise in Wednesday Trading
Express News | CDC Confirms First Severe Case Of H5N1 Bird Flu In U.S. On December 13; Patient Hospitalized With Severe Case Of Avian Influenza A Virus Infection In Louisiana
Sanofi (SNY.US) successfully introduced the TL1A monoclonal antibody for the treatment of inflammatory bowel disease in a Phase IIb study with an investment of 1.5 billion dollars.
In October 2023, Sanofi (SNY.US) reached an agreement with Teva for the development and commercialization of the drug, with an upfront payment of 0.5 billion dollars and milestone payments of up to 1 billion dollars.
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
